NeuroOne Medical Technologies Corp

NeuroOne Medical Technologies Corp. is a medical technology company, which engages in the development and commercialization of thin film electrode technology for continuous electroencephalogram and stereoelectrocencephalography recording, spinal cord stimulation, brain stimulation, and ablation solutions. The company was founded by Mark Christianson on August 20, 2009 and is headquartered in Eden Prairie, MN.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

NeuroOne Medical Technologies Corp excels in Q2 2024 performance

NeuroOne Medical Technologies Corp demonstrated strong commercial and financial performance in Q2 2024.
The company's focus on innovation, strategic partnerships, and diverse product development is driving growth.
While facing challenges in capital management and market competition, NeuroOne is well-positioned for future success.
Opportunities in product diversification, market expansion, and fundraising set the stage for continued growth and profitability.

NeuroOne Medical Technologies Corp reports strong Q3 performance and expansion opportunities

NMTC's Q3 2024 performance reflects progress in commercialization and product revenue growth, supported by strategic financing initiatives.
While facing challenges in managing expenses and achieving profitability, the company is well-positioned to capitalize on distribution agreements and product expansion.
With a focus on innovation and market penetration, NMTC is poised for growth through new FDA applications and leveraging its technological advancements.

NeuroOne Medical Technologies Corp achieves FDA clearance and revenue growth

NeuroOne Medical Technologies Corp made significant strides in product development, securing partnerships, and achieving FDA clearance, positioning the company for growth.
While facing challenges in stock price compliance and market competition, the company's focus on innovation and revenue growth presents opportunities for expansion.
With a strong financial performance in 2024 and revenue growth projections for 2025, NeuroOne is poised to capitalize on market demand and technological advancements.
By diversifying product applications and exploring new partnerships, NeuroOne aims to drive market penetration and establish itself as a key player in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q1 2023 Earnings Conference Call February 14, 2023 4:30 AM ET Company Participants Dave Rosa - President and CEO Ron McClurg - CFO Conference Call Participants Alex Nowak - Craig Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation First Quarter Fiscal Year 2023 Financial Results Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) Q1 2023 Earnings Call Transcript

EDEN PRAIRIE, Minn. , Feb. 14, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the fiscal first quarter 2023 ended December 31, 2022.

NeuroOne® Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

EDEN PRAIRIE, Minn. , Feb. 9, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal first quarter 2023 ended December 31, 2022 and provide a corporate update on February 14, 2023 at 4:30 PM Eastern Time.

NeuroOne® to Report First Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on February 14

Company highlights fiscal year 2022 and subsequent achievements, catalysts for fiscal year 2023 EDEN PRAIRIE, Minn. , Jan. 30, 2023 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has issued a Winter 2023 Letter to Shareholders.

NeuroOne® Issues Letter to Shareholders

EDEN PRAIRIE, Minn. , Dec. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces financial results for the fiscal fourth quarter and full fiscal year ended September 30, 2022.

NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2022 Financial Results

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q4 2022 Results Conference Call December 13, 2022 4:30 PM ET Company Participants Dave Rosa - President and Chief Executive Officer Ron McClurg - Chief Financial Officer Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Corporate Update Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) Q4 2022 Earnings Call Transcript

EDEN PRAIRIE, Minn. , Dec. 13, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; "NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, to host fiscal Fourth Quarter Corporate Update for the period ended September 30, 2022.

NeuroOne® to Host Fiscal Fourth Quarter Corporate Update

EDEN PRAIRIE, Minn. , Dec. 8, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its fiscal fourth quarter and full fiscal year ended September 30, 2022, and provide a corporate update, on December 13, 2022 at 4:30 PM Eastern Time.

NeuroOne® to Report Fourth Quarter and Fiscal Year 2022 Financial Results and Provide Corporate Update on December 13

Animal study completed under the guidance of Dr. Jamie Van Gompel at the Mayo Clinic in Rochester, MN Company on track to submit OneRF 510(k) application to the FDA in the second quarter of calendar year 2023 EDEN PRAIRIE, Minn. , Dec. 6, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has successfully completed a feasibility study with its OneRF™ ablation system, a developing technology that utilizes existing implanted sEEG diagnostic electrodes for brain tissue lesioning.

NeuroOne® Successfully Completes Feasibility Study with its OneRF™ Ablation System

Company focused on manufacturing and commercialization in partnership with Zimmer Biomet EDEN PRAIRIE, Minn. , Nov. 30, 2022 /PRNewswire/ --  NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it shipped the first commercial order to Zimmer Biomet for its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

NeuroOne® Ships Initial Zimmer Biomet Order for its Evo® sEEG System for Less than 30 Day Use

Ceremony to commemorate recent FDA clearance milestone for Company's Evo® sEEG Electrode technology EDEN PRAIRIE, Minn. , Nov. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it will ring the Nasdaq closing bell today Tuesday, November 22, 2022, to commemorate its recent corporate milestone achievement for the Evo® thin film electrode platform.

NeuroOne® to Ring Nasdaq Stock Market Closing Bell on November 22

CytomX Therapeutics

Ensysce Biosciences

Nexalin Technology Inc

Taysha Gene Therapies

Biotech penny stocks to watch this week. Are they a buy now?

Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week

EDEN PRAIRIE, Minn. , Nov. 21, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces an appearance by Chief Executive Officer Dave Rosa on Fox Business Network's Mornings with Maria earlier today.

NeuroOne® CEO Dave Rosa Featured on Fox Business Network's 'Mornings with Maria'

Company focused on manufacturing ramp for commercialization in partnership with Zimmer Biomet EDEN PRAIRIE, Minn. , Oct. 25, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.

NeuroOne® Receives FDA 510(k) Clearance to Market its Evo® sEEG System for Less than 30 Day Use

EDEN PRAIRIE, Minn. , Sept. 22, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective September 20, 2022, the Compensation Committee of the Board of Directors approved two equity awards under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the "Inducement Plan"), as a material inducement to the individuals entering into employment with the Company.

NeuroOne Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q3 2022 Earnings Conference Call August 11, 2022 5:30 PM ET Company Participants Dave Rosa - President and Chief Executive Officer Ron McClurg - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group Ben Haynor - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. And welcome to the NeuroOne Medical Technologies Corporation Third Quarter of Fiscal Year 2022 Financial Results Conference Call.

NeuroOne Medical Technologies Corporation (NMTC) CEO Dave Rosa on Q3 2022 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn. , Aug. 11, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the third quarter of fiscal year 2022 ended June 30, 2022.

NeuroOne® Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Company re-submits application to gain FDA clearance for less than 30 day use EDEN PRAIRIE, Minn. , Aug. 9, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company submitted a special 510(k) to the U.S. Food and Drug Administration ("FDA") on August 8 th for its sEEG electrode to extend the duration of use from less than 24 hours to less than 30 day use.

NeuroOne® Submits Special 510(k) to FDA for Evo® sEEG Electrode

EDEN PRAIRIE, Minn. , Aug. 4, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call to discuss financial results for its third quarter of fiscal 2022 ended June 30, 2022, on August 11, 2022 at 5:30 PM Eastern Time.

NeuroOne® to Report Third Quarter Fiscal Year 2022 Financial Results on August 11

Amendment provides Zimmer Biomet with 350,000 warrants with exercise price of $3.00 per share EDEN PRAIRIE, Minn. , Aug. 3, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the Company entered into an amendment to its Exclusive Development and Distribution Agreement with Zimmer Biomet, Inc. ("Zimmer") that will provide the Company with a $3.5 million accelerated payment within 10 business days which relates to certain milestone payments.

NeuroOne® Announces $3.5 Million Accelerated Milestone Payment from Zimmer Biomet for Evo® sEEG Electrode

Case performed at Emory University for intraoperative brain mapping EDEN PRAIRIE, Minn. , July 12, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the first clinical case using the Evo sEEG electrode was performed by Dr. Robert Gross at Emory University.

NeuroOne® Announces First Clinical Case Using Evo® sEEG Electrode

Letter recaps key highlights of fiscal year 2021 and features upcoming milestones for fiscal year 2022 and beyond EDEN PRAIRIE, Minn. , June 2, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced the publication of the 2022 Annual Letter to Shareholders published in the Company's Proxy Statement for its Annual Meeting of Stockholders that occurred on May 31, 2022.

NeuroOne® Issues Letter to Stockholders in Connection With 2022 Annual Meeting of Stockholders

EDEN PRAIRIE, Minn. , May 19, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ:  NMTC ) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will present at the H.C.

NeuroOne® to Present Its Breakthrough Technology for Monitoring Neural Activity at the H.C. Wainwright Global Investment Conference on May 25

The Evo®  sEEG electrode 510(k) cleared for temporary (less than 24 hours) use remains in effect and the Company will explore the opportunity to market the device for intraoperative use. EDEN PRAIRIE, Minn.

NeuroOne Provides Evo® sEEG Update

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC ) Q2 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Dave Rosa – Chief Executive Officer Ron Mcclurg – Chief Financial Officer Conference Call Participants Connor Stevenson – Craig-Hallum Ben Haynor – Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by, and welcome to the NeuroOne Medical Technologies Corporation Second Quarter of Fiscal 2022 Earnings Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and its Chief Financial Officer, Ron Mcclurg.

News for NeuroOne Medical Technologies Corp Stock (NMTC)